Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)
Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W., Galanis, E., Shah, Sunjay, Abrams, Ross A. , Curran, Walter J. , Buckner, Jan C. , Shaw, Edward G. , O'Neill, Brian P, Galanis, Eva, Shah, Sunjay A, O’Neill, Brian Patrick , Giannini, Caterina

Neuro-Oncology Practice | November 5, 2015 | Volume: 2 | Issue: 4 | Pages: 199-204

10.1093/nop/npv031 | PMID 26640699 Get It

Abstract Background Pilocytic astrocytoma is a rare tumor in adults. This report is of a prospective clinical trial with long-term follow-up. Methods Between 1986 and 1994, 20 eligible adults with supratentorial pilocytic astrocytomas were enrolled in a prospective intergroup trial of radiotherapy (RT) after biopsy (3 patients) or observation after gross (11 patients) or subtotal (6 patients) resection. Results At the time of analysis (median follow-up, 20.8 years), 2 patients (10%) have died and 18 patients (90%) are alive. Neurologic and cognitive function were stable or improved over time for the majority of patients. No toxic effects of treatment or malignant transformations have been recorded at last follow-up. For the entire cohort the 20-year time to progression and overall survival rates are 95% and 90% respectively. The cause of death (2.2 and 16.1 years after enrollment) in both patients was unrelated to tumor although both were biopsy-only patients. One subtotally resected tumor progressed 1 month after enrollment requiring P32 injection into an enlarging cyst. Because of further progression this patient required RT 18 months later. This patient is alive without evidence of progression 18 years after RT. Conclusion The long-term follow-up results of this prospective trial confirm that adults with pilocytic astrocytomas have a favorable prognosis with regard to survival and neurologic function. Close observation is recommended for adults with pilocytic astrocytomas, reserving RT for salvage, as the majority remain stable after gross or subtotal resection and no adjuvant therapy.
Evaluation of a Genus- and Group-Specific Rapid PCR Assay Panel on Synovial Fluid for Diagnosis of Prosthetic Knee Infection
Melendez, Dante P. , Greenwood‐Quaintance, Kerryl E. , Berbari, Elie F. , Osmon, Douglas R. , Mandrekar, Jayawant N. , Hanssen, Arlen D. , Patel, Robin , Patel, Robin

Journal of Clinical Microbiology | November 5, 2015 | Volume: 54 | Issue: 1 | Pages: 120-126

10.1128/jcm.02302-15 | PMID 26537446 Get It

ABSTRACT We evaluated a genus- and group-specific PCR assay panel using 284 prosthetic knee synovial fluid samples collected from patients presenting to our institution with implant failure. Using the Musculoskeletal Infection Society diagnostic criteria, 88 and 196 samples were classified as showing prosthetic joint infection (PJI) and aseptic failure (AF), respectively. Sensitivities of the synovial fluid PCR panel and culture were 55.6% and 76.1% ( P ≤ 0.001), respectively, and specificities were 91.8% and 97.4% ( P = 0.016), respectively. Among the 70 subjects who had received antibiotics within the month preceding synovial fluid aspiration (48 of whom had PJI), PCR panel and synovial fluid culture sensitivities were 64.5% and 85.4%, respectively ( P < 0.0001). In this group, the PCR panel detected Staphylococcus aureus in two culture-negative PJI cases. Overall, the evaluated molecular diagnostic tool had low sensitivity when applied to synovial fluid.
Regenerative Medicine Build-Out
Pfenning, Michael, Harper, C. Michel , Pfenning, Michael A, Terzic, André , Gores, Gregory J.

Stem Cells Translational Medicine | November 5, 2015 | Volume: 4 | Issue: 12 | Pages: 1373-1379

10.5966/sctm.2015-0275 | PMID 26537392 Get It

Abstract Summary Regenerative technologies strive to boost innate repair processes and restitute normative impact. Deployment of regenerative principles into practice is poised to usher in a new era in health care, driving radical innovation in patient management to address the needs of an aging population challenged by escalating chronic diseases. There is urgency to design, execute, and validate viable paradigms for translating and implementing the science of regenerative medicine into tangible health benefits that provide value to stakeholders. A regenerative medicine model of care would entail scalable production and standardized application of clinical grade biotherapies supported by comprehensive supply chain capabilities that integrate sourcing and manufacturing with care delivery. Mayo Clinic has rolled out a blueprint for discovery, translation, and application of regenerative medicine therapies for accelerated adoption into the standard of care. To establish regenerative medical and surgical service lines, the Mayo Clinic model incorporates patient access, enabling platforms and delivery. Access is coordinated through a designated portal, the Regenerative Medicine Consult Service, serving to facilitate patient/provider education, procurement of biomaterials, referral to specialty services, and/or regenerative interventions, often in clinical trials. Platforms include the Regenerative Medicine Biotrust and Good Manufacturing Practice facilities for manufacture of clinical grade products for cell-based, acellular, and/or biomaterial applications. Care delivery leverages dedicated interventional suites for provision of regenerative services. Performance is tracked using a scorecard system to inform decision making. The Mayo Clinic roadmap exemplifies an integrated organization in the discovery, development, and delivery of regenerative medicine within a growing community of practice at the core of modern health care. Significance Regenerative medicine is at the vanguard of health care poised to offer solutions for many of today's incurable diseases. Accordingly, there is a pressing need to develop, deploy, and demonstrate a viable framework for rollout of a regenerative medicine model of care. Translation of regenerative medicine principles into practice is feasible, yet clinical validity and utility must be established to ensure approval and adoption. Standardized and scaled-up regenerative products and services across medical and surgical specialties must in turn achieve a value-added proposition, advancing intended outcome beyond current management strategies.
Sulfate and thiosulfate inhibit oxalate transport via a dPrestin (Slc26a6)-dependent mechanism in an insect model of calcium oxalate nephrolithiasis
Landry, Greg M. , Hirata, Taku, Anderson, Jacob B. , Cabrero, Pablo , Gallo, C. , Dow, Julian A. T. , Romero, Michael F. , Gallo, Christopher J R, Dow, Julian A T , Romero, Michael F , Anderson, Jacob B

American Journal of Physiology-Renal Physiology | November 5, 2015 | Volume: 310 | Issue: 2 | Pages: F152-F159

10.1152/ajprenal.00406.2015 | PMID 26538444 Get It

Nephrolithiasis is one of the most common urinary tract disorders, with the majority of kidney stones composed of calcium oxalate (CaOx). Given its prevalence (US occurrence 10%), it is still poorly understood, lacking progress in identifying new therapies because of its complex etiology. Drosophila melanogaster (fruitfly) is a recently developed model of CaOx nephrolithiasis. Effects of sulfate and thiosulfate on crystal formation were investigated using the Drosophila model, as well as electrophysiological effects on both Drosophila (Slc26a5/6; dPrestin) and mouse (mSlc26a6) oxalate transporters utilizing the Xenopus laevis oocyte heterologous expression system. Results indicate that both transport thiosulfate with a much higher affinity than sulfate Additionally, both compounds were effective at decreasing CaOx crystallization when added to the diet. However, these results were not observed when compounds were applied to Malpighian tubules ex vivo. Neither compound affected CaOx crystallization in dPrestin knockdown animals, indicating a role for principal cell-specific dPrestin in luminal oxalate transport. Furthermore, thiosulfate has a higher affinity for dPrestin and mSlc26a6 compared with oxalate These data indicate that thiosulfate's ability to act as a competitive inhibitor of oxalate via dPrestin, can explain the decrease in CaOx crystallization seen in the presence of thiosulfate, but not sulfate. Overall, our findings predict that thiosulfate or oxalate-mimics may be effective as therapeutic competitive inhibitors of CaOx crystallization.
ISDN2014_0272: Reversing neurodevelopmental disorders: Successful intervention for eye poking in a girl with Potocki–Chaffer Syndrome
Tervo, Raymond C., Harth, Jacqueline M., Hoch, John , Cote, Erin, Byiers, Breanne J.

International Journal of Developmental Neuroscience | November 5, 2015 | Volume: 47 | Issue: Part_A | Pages: 81-81

10.1016/j.ijdevneu.2015.04.221 Get It

ISDN2014_0276: Peripheral innervation in children with developmental delay: A risk marker for self‐injurious behavior?
Tervo, Raymond C., Symons, Frank J. , Damerow, John A., Suski, Erica, Foster, S., Panoutsopoulou, Ioanna G., Wendelschafer‐Crabb, Gwen, Burkitt, Chantel C. , McAdams, Brian , Kennedy, William R.

International Journal of Developmental Neuroscience | November 5, 2015 | Volume: 47 | Issue: Part_A | Pages: 82-82

10.1016/j.ijdevneu.2015.04.224 Get It

Food Restriction Ameliorates the Development of Polycystic Kidney Disease
Warner, Gina, Hein, Kyaw Zaw , Nin, Verónica , Edwards, Marika, Chini, Claudia C.S. , Harris, Peter C. , Torres, Vicente E. , Chini, Eduardo N. , Hopp, Katharina , Harris, Peter C , Torres, Vicente E

Journal of the American Society of Nephrology | November 4, 2015 | Volume: 27 | Issue: 5 | Pages: 1437-1447

10.1681/asn.2015020132 | PMID 26538633 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the accumulation of kidney cysts that ultimately leads to loss of renal function and kidney failure. At present, the treatment for ADPKD is largely supportive. Multiple studies have focused on pharmacologic approaches to slow the development of the cystic disease; however, little is known about the role of nutrition and dietary manipulation in PKD. Here, we show that food restriction (FR) effectively slows the course of the disease in mouse models of ADPKD. Mild to moderate (10%–40%) FR reduced cyst area, renal fibrosis, inflammation, and injury in a dose-dependent manner. Molecular and biochemical studies in these mice indicate that FR ameliorates ADPKD through a mechanism involving suppression of the mammalian target of the rapamycin pathway and activation of the liver kinase B1/AMP-activated protein kinase pathway. Our data suggest that dietary interventions such as FR, or treatment that mimics the effects of such interventions, may be potential and novel preventive and therapeutic options for patients with ADPKD.
Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil
Ungprasert, Patompong , Chowdhary, V. Rajesh, Davis, Mike , Makol, Ashima , Makol, Ashima

Lupus | November 4, 2015 | Volume: 25 | Issue: 4 | Pages: 427-430

10.1177/0961203315615221 | PMID 26537421 Get It

Hematological abnormalities, such as anemia, leucopenia, and thrombocytopenia, secondary to peripheral destruction, are common in systemic lupus erythematosus (SLE). However, cytopenias from autoimmune myelofibrosis (AIMF) are extremely uncommon in SLE, with less than 40 reported cases in the literature. We report the case of a 33-year-old female who presented with bullous skin lesions and pancytopenia as the presenting manifestation of what was ultimately diagnosed as SLE with AIMF. She responded well to glucocorticoids and mycophenolate mofetil.
Hormonal response to energy restriction
Lanza, Ian R. , Lanza, Ian R

Science Translational Medicine | November 4, 2015 | Volume: 7 | Issue: 312 | Pages: No page available

10.1126/scitranslmed.aad5505 Get It

Humans and rodents differ in their hormonal responses to chronic caloric restriction.
Langerhans cell histiocytosis of the temporal bone: A review of 29 cases at a single center
Modest, Mara C., García, Joaquín J. , Arndt, Carola, Carlson, Matthew L. , Arndt, Carola S

The Laryngoscope | November 4, 2015 | Volume: 126 | Issue: 8 | Pages: 1899-1904

10.1002/lary.25773 | PMID 26535795 Get It

Objectives/HypothesisEvaluate presentation, management, and clinical outcomes of patients with temporal bone Langerhans cell histiocytosis (LCH).Study DesignRetrospective chart review.MethodsReviewed all patients with temporal bone LCH at a tertiary academic referral center between 1978 and 2014. Presentation, disease course, intervention, and clinical outcomes were analyzed.ResultsBetween 1978 and 2014, 29 temporal bones in 20 patients (12 males; median age 32 years, range 1.3–88 years) were diagnosed with temporal bone LCH, representing 4% of all patients diagnosed with LCH at our institution during that time. Twelve (60%) patients presented purely with head and neck disease, nine (45%) with bilateral temporal bone involvement, seven (35%) with intracranial spread, and eight (40%) with multisystem disease. The most common presenting symptoms were otorrhea (n = 11; 55%) and subjective hearing loss (n = 10; 50%). Treatment included primary chemotherapy or radiation alone(n = 7; 35%), local resection alone (n = 2; 10%), and chemotherapy or radiation with surgery(n = 11; 55%). Ten patients suffered local or systemic relapse (50%; median 12 months). Median follow‐up for patients was 31 months. One patient died secondary to pulmonary complications of multisystem LCH.ConclusionsLCH is an uncommon histiocytic disorder with a range of clinical manifestations and disease severity. Otologic involvement is rare, and frequently manifests with symptoms similar to otomastoiditis. Evaluation and close follow‐up of both ears is important. Bilateral simultaneous or sequential LCH can be seen in up to 45% of cases. Patients with temporal bone LCH should be managed by a multidisciplinary team with treatment tailored to the patient. Relapse is more common in patients with multisystem involvement. Even in subjects with isolated otologic involvement, long‐term follow‐up is critical, with relapses occurring years beyond treatment.Level of Evidence4. Laryngoscope, 126:1899–1904, 2016